NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 26,011 Shares of Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 26,011 shares of the business’s stock in a transaction dated Wednesday, December 24th. The stock was sold at an average price of $35.68, for a total transaction of $928,072.48. Following the completion of the transaction, the chief accounting officer directly owned 15,000 shares of the company’s stock, valued at approximately $535,200. This represents a 63.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Louise Frederika Kooij also recently made the following trade(s):

• On Friday, December 26th, Louise Frederika Kooij sold 43,872 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.30, for a total transaction of $1,548,681.60.
• On Tuesday, December 23rd, Louise Frederika Kooij sold 75,117 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $36.21, for a total transaction of $2,719,986.57.

NewAmsterdam Pharma Stock Performance

Shares of NAMS opened at $35.02 on Tuesday. The business’s fifty day moving average price is $37.03 and its two-hundred day moving average price is $29.13. The firm has a market capitalization of $3.97 billion, a price-to-earnings ratio of -17.08 and a beta of 0.05. NewAmsterdam Pharma Company N.V. has a 52 week low of $14.06 and a 52 week high of $42.00.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.03). The firm had revenue of $0.35 million for the quarter, compared to the consensus estimate of $4.54 million. NewAmsterdam Pharma had a negative return on equity of 28.30% and a negative net margin of 627.59%. As a group, research analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current year.

Hedge Funds Weigh In On NewAmsterdam Pharma

A number of hedge funds and other institutional investors have recently made changes to their positions in NAMS. Capital World Investors raised its stake in NewAmsterdam Pharma by 17.1% during the 3rd quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock worth $279,358,000 after buying an additional 1,434,986 shares during the period. RA Capital Management L.P. grew its stake in NewAmsterdam Pharma by 14.6% in the first quarter. RA Capital Management L.P. now owns 10,138,938 shares of the company’s stock valued at $207,544,000 after acquiring an additional 1,293,938 shares during the period. Jennison Associates LLC increased its holdings in shares of NewAmsterdam Pharma by 42.5% in the third quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock worth $119,407,000 after acquiring an additional 1,252,451 shares in the last quarter. Duquesne Family Office LLC increased its holdings in shares of NewAmsterdam Pharma by 131.2% in the third quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company’s stock worth $54,710,000 after acquiring an additional 1,091,525 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. raised its position in shares of NewAmsterdam Pharma by 54.5% during the second quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock worth $54,566,000 after purchasing an additional 1,062,359 shares during the period. 89.89% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently commented on NAMS. Needham & Company LLC lifted their price target on shares of NewAmsterdam Pharma from $40.00 to $46.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Citigroup lifted their target price on shares of NewAmsterdam Pharma from $42.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, October 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Wednesday, October 8th. Stifel Nicolaus raised their price target on NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Finally, Royal Bank Of Canada upped their price objective on NewAmsterdam Pharma from $39.00 to $44.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, NewAmsterdam Pharma has a consensus rating of “Moderate Buy” and a consensus price target of $45.90.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.